These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7363400)

  • 61. [Histochemical and biochemical assays of estrogen receptors in breast cancer and significance of endocrine therapy].
    Tominaga T
    Gan No Rinsho; 1983 May; 29(6):628-31. PubMed ID: 6308307
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy.
    Morgan DA; Refalo NA; Cheung KL
    Breast; 2011 Jun; 20(3):215-9. PubMed ID: 21159509
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Urinary androgens and tumor estrogen receptor as predictors of ovariectomy response and of survival in advanced breast cancer.
    Oriana S; Secreto G; Di Fronzo G; Torri A
    Breast Cancer Res Treat; 1987; 9(3):201-5. PubMed ID: 3663955
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical predictive criteria for response to endocrine treatment and the receptor status.
    Maass H; Jonat W
    Recent Results Cancer Res; 1980; 71():26-9. PubMed ID: 7378140
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Relationships between oestrogen receptor,epidermal growth factor receptor, ER-D5, and P24 oestrogen regulated protein in human breast cancer.
    Horne GM; Angus B; Wright C; Needham G; Nicholson S; Harris AL; Innes B; Horne CH
    J Pathol; 1988 Jun; 155(2):143-50. PubMed ID: 3292735
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
    Swain SM; Wilson JW; Mamounas EP; Bryant J; Wickerham DL; Fisher B; Paik S; Wolmark N
    J Natl Cancer Inst; 2004 Apr; 96(7):516-23. PubMed ID: 15069113
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Oestrogen receptors and the response to endocrine therapy in advanced breast cancer.
    Roberts MM; Rubens RD; King RJ; Hawkins RA; Millis RR; Hayward JL; Forrest AP
    Br J Cancer; 1978 Sep; 38(3):431-6. PubMed ID: 708575
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Steroid hormone receptors in breast cancer].
    Nomura Y
    Rinsho Byori; 1990 Jan; 38(1):26-30. PubMed ID: 2308219
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Estrogen receptors and breast cancer: prognostic and therapeutic implications.
    Gapinski PV; Donegan WL
    Surgery; 1980 Sep; 88(3):386-93. PubMed ID: 7414516
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Variations in steroid receptor status with disease stage in breast cancer.
    Stebbings WS; Anderson E; Puddefoot JR; Vinson GP; Gilmore OJ; Plowman PN
    Eur J Surg Oncol; 1989 Aug; 15(4):322-7. PubMed ID: 2759250
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The lack of relationship between estrogen receptor status and response to chemotherapy.
    Hilf R; Feldstein ML; Savlov ED; Gibson SL; Seneca B
    Cancer; 1980 Dec; 46(12 Suppl):2797-800. PubMed ID: 7448724
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Oestrogen receptors and primary breast cancer.
    Humeniuk V; Hawkins RA; Prescott RJ; Roberts MM; Stewart HJ; Forrest AP
    Aust N Z J Surg; 1982 Aug; 52(4):408-14. PubMed ID: 6956318
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Significance of estrogen receptor assay in cytotoxic chemotherapy in relation to previous endocrine therapy of advanced breast cancer patients.
    Nomura Y; Yamagata J; Kondo H
    Gan; 1979 Aug; 70(4):473-82. PubMed ID: 510847
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer.
    Ellis PA; Saccani-Jotti G; Clarke R; Johnston SR; Anderson E; Howell A; A'Hern R; Salter J; Detre S; Nicholson R; Robertson J; Smith IE; Dowsett M
    Int J Cancer; 1997 Aug; 72(4):608-13. PubMed ID: 9259399
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pure oestrogen antagonists for the treatment of advanced breast cancer.
    Howell A
    Endocr Relat Cancer; 2006 Sep; 13(3):689-706. PubMed ID: 16954425
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer. Norwegian Breast Cancer Group.
    Gundersen S; Kvinnsland S; Klepp O; Lund E; Hannisdal E; Høst H
    Eur J Cancer; 1992; 28(2-3):390-4. PubMed ID: 1534248
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Chemotherapy for oestrogen-receptor-negative breast cancer.
    Yerushalmi R; Gelmon K
    Lancet; 2008 Jan; 371(9606):4-5. PubMed ID: 18177755
    [No Abstract]   [Full Text] [Related]  

  • 78. Relationship between steroid receptors and response to endocrine therapy and cytotoxic chemotherapy in metastatic breast cancer.
    Young PC; Ehrlich CE; Einhorn LH
    Cancer; 1980 Dec; 46(12 Suppl):2961-3. PubMed ID: 7448744
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis.
    Glück S; Russell C; O'Shaughnessy J; McKenna EF; Hu S; Odom D; Blum JL
    Breast; 2013 Dec; 22(6):1087-93. PubMed ID: 24095220
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.
    Torrisi R; Bagnardi V; Pruneri G; Ghisini R; Bottiglieri L; Magni E; Veronesi P; D'Alessandro C; Luini A; Dellapasqua S; Viale G; Goldhirsch A; Colleoni M
    Br J Cancer; 2007 Sep; 97(6):802-8. PubMed ID: 17712311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.